Innovating Works

ROCHE DIAGNOSTICS GMBH

Desconocido
CAARE: Characterization and Recovery of Bionanoparticles for Vaccine Delivery and Gene Therapy The Doctoral Network CAARE - Characterization and Recovery of Bionanoparticles for Vaccine Delivery and Gene Therapy focuses on a rapidly em...
2024-06-25 - 2028-09-30 | Financiado
Protambbody: Proteasomal degradation of toxic intracellular amyloid-beta protein by nanobody-enabled proximity to... ROCHE DIAGNOSTICS GMBH participó en un HORIZON EUROPE: HORIZON-MSCA-2021-PF-01 The amyloid-beta (Aβ) protein arises from the sequential proteolytic cleavage of Aβ precursor protein (APP). The accumulation of Aβ oligomer...
2022-06-08 - 2025-06-30 | Financiado
VIMS: Virtual IoT Maintenance System ROCHE DIAGNOSTICS GMBH participó en un H2020: H2020-EIC-FTI-2018-2020 The objective of the VIMS (Virtual IoT Maintenance System) project consists in developing and industrializing a new, complete, and integrate...
2019-10-11 - 2022-04-30 | Financiado
MLFPM2018: Machine Learning Frontiers in Precision Medicine ROCHE DIAGNOSTICS GMBH participó en un H2020: H2020-MSCA-ITN-2018 Healthcare is entering the digital era: More and more patient data, from the molecular level of genome sequences to the level of image pheno...
2018-08-20 - 2024-03-31 | Financiado
EPIDIVERSE: Epigenetic Diversity in Ecology ROCHE DIAGNOSTICS GMBH participó en un H2020: H2020-MSCA-ITN-2017 Plants are the foundation of all ecosystems and they provide humans with essential services. Unprecedented rates of global environmental cha...
2017-08-29 - 2022-02-28 | Financiado
inSSIght: In depth support for innovation and exploitation in Smart Systems Integration ROCHE DIAGNOSTICS GMBH participó en un H2020: H2020-ICT-2016-2017 The objective of the proposed CSA is to support and complement R&I activities in Smart Systems Integration (SSI) by structuring industrial c...
2016-10-11 - 2018-12-31 | Financiado
GlyCoCan: Exploiting Glycosylation of Colorectal Cancer for the development of improved diagnostics and therap... ROCHE DIAGNOSTICS GMBH participó en un H2020: H2020-MSCA-ITN-2015 Colorectal cancer (CRC) is a major worldwide cancer burden with about 1.4 million cases in 2012 and an annual mortality of approximately 700...
2015-08-07 - 2019-08-31 | Financiado
IMMUTRAIN: Training Network for the Immunotherapy of Cancer ROCHE DIAGNOSTICS GMBH participó en un H2020: H2020-MSCA-ITN-2014 In the European Union, cancer is the leading cause of death and the overall cancer incidence is still increasing. As a result of expanding e...
2015-06-12 - 2019-11-30 | Financiado
CELL-O-MATIC: High Throughput Systematic Single Cell Genomics using Micro Nano Fluidic Chips for Extracting Pre a... ROCHE DIAGNOSTICS GMBH participó en un FP7: We propose a technology that will sit at the front-end of sequencing pipelines, present and future, and will significantly enhance the quali...
Financiado
GLYCOPHARM: The Sugar Code from bio chemical concept to clinics ROCHE DIAGNOSTICS GMBH participó en un FP7: Coding of biochemical information is commonly described to be based solely on nucleotides and amino acids, whereas carbohydrates, the most a...
Financiado
EMBEK1: Development and analysis of polymer based multi functional bactericidal materials ROCHE DIAGNOSTICS GMBH participó en un FP7: 90% of bacteria are found attached to solid surfaces forming structures (bio-films), that are inaccessible to drugs and antibiotics. These b...
Financiado
DETECTIVE: Detection of endpoints and biomarkers of repeated dose toxicity using in vitro systems ROCHE DIAGNOSTICS GMBH participó en un FP7: Assessment of repeated dose toxicity is a standard requirement in human safety evaluation and relies on animal testing as no alternatives ar...
Financiado
CHEBANA: Chemical Bioanalysis ROCHE DIAGNOSTICS GMBH participó en un FP7: Chemical Bioanalysis aims for retrieving selective information out of complex biological systems. Sensors, probes and devices are the future...
Financiado
GOCARB: Type 1 Diabetes Self Management and Carbohydrate Counting A Computer Vision based Approach ROCHE DIAGNOSTICS GMBH participó en un FP7: Patients with diabetes must be taught how to achieve glycaemic control by monitoring their glucose levels properly. They are medicated with...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.